Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Identification, Characterization and HPLC Quantification of Process-Related Impurities in Bepotastine Besilate Bulk Drug.

Zhang C, Han C, Sun L, Yu J, Zou Q.

Drug Res (Stuttg). 2019 Sep 20. doi: 10.1055/a-0831-2401. [Epub ahead of print]

PMID:
31539916
2.

Identification, Characterization, and Quantification of Impurities of Safinamide Mesilate: Process-Related Impurities and Degradation Products.

Zou L, Sun L, Zhang H, Hui W, Zou Q, Zhu Z.

J AOAC Int. 2017 Jul 1;100(4):1029-1037. doi: 10.5740/jaoacint.16-0218. Epub 2017 Feb 2.

PMID:
28150570
3.

Bepotastine.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

4.

Structural elucidation of potential impurities in Azilsartan bulk drug by HPLC.

Zhou W, Zhou Y, Sun L, Zou Q, Wei P, Ouyang P.

J AOAC Int. 2014 Nov-Dec;97(6):1552-62.

PMID:
25632433
5.

Stability-indicating reversed-phase HPLC method development and characterization of impurities in vortioxetine utilizing LC-MS, IR and NMR.

Liu L, Cao N, Ma X, Xiong K, Sun L, Zou Q, Yao L.

J Pharm Biomed Anal. 2016 Jan 5;117:325-32. doi: 10.1016/j.jpba.2015.08.028. Epub 2015 Aug 22.

PMID:
26412721
6.
7.

Identification, Characterization and Quantification of Process-Related and Degradation Impurities in Lisdexamfetamine Dimesylate: Identifiction of Two New Compounds.

Gao S, Meng L, Zhao C, Zhang T, Qiu P, Zhang F.

Molecules. 2018 Nov 29;23(12). pii: E3125. doi: 10.3390/molecules23123125.

8.

Identification, characterization and HPLC quantification of process-related impurities in Trelagliptin succinate bulk drug: Six identified as new compounds.

Zhang H, Sun L, Zou L, Hui W, Liu L, Zou Q, Ouyang P.

J Pharm Biomed Anal. 2016 Sep 5;128:18-27. doi: 10.1016/j.jpba.2016.04.041. Epub 2016 May 10.

PMID:
27209451
9.

Validated gradient stability indicating HPLC method for determining Diltiazem Hydrochloride and related substances in bulk drug and novel tablet formulation.

Chatpalliwar VA, Porwal PK, Upmanyu N.

J Pharm Anal. 2012 Jun;2(3):226-237. doi: 10.1016/j.jpha.2012.01.003. Epub 2012 Feb 4.

10.

Structural elucidation of the impurities in Enzalutamide bulk drug and the development, validation of corresponding HPLC method.

Ma X, Zhou W, Zou Q, Ouyang P.

J Pharm Biomed Anal. 2016 Nov 30;131:436-443. doi: 10.1016/j.jpba.2016.08.036. Epub 2016 Sep 2.

PMID:
27664386
11.

Development and validation of a selective, sensitive and stability indicating UPLC-MS/MS method for rapid, simultaneous determination of six process related impurities in darunavir drug substance.

A VBR, Yusop Z, Jaafar J, Aris AB, Majid ZA, Umar K, Talib J.

J Pharm Biomed Anal. 2016 Sep 5;128:141-148. doi: 10.1016/j.jpba.2016.05.026. Epub 2016 May 18.

PMID:
27262107
12.

Development and Validation of a Stability-Indicating RP-HPLC Method for the Estimation of Drotaverine Impurities in API and Pharmaceutical Formulation.

Thummala VR, Tharlapu SS, Rekulapalli VK, Ivaturi MR, Nittala SR.

Sci Pharm. 2013 Oct 21;82(1):99-115. doi: 10.3797/scipharm.1309-06. Print 2014 Jan-Mar.

13.

Identification, synthesis and structural characterization of process related and degradation impurities of acrivastine and validation of HPLC method.

Kumar A, Devineni SR, Dubey SK, Kumar P, Srivastava V, Ambulgekar G, Jain M, Gupta DK, Singh G, Kumar R, Hiriyanna SG, Kumar P.

J Pharm Biomed Anal. 2017 Jan 30;133:15-26. doi: 10.1016/j.jpba.2016.10.015.

PMID:
27969063
14.

Identification and Characterization of Asulam Impurities in Self Made Bulk Batch Synthesis and Quantification by RP-HPLC Method.

Mahaboob Basha D, Venkata Reddy G, Gopi Krishna Y, Kumara Swamy BE, Vijay R.

J AOAC Int. 2018 Sep 1;101(5):1448-1460. doi: 10.5740/jaoacint.17-0316. Epub 2018 Apr 19.

PMID:
29673416
15.

Stability profiling of anti-malarial drug piperaquine phosphate and impurities by HPLC-UV, TOF-MS, ESI-MS and NMR.

Yan F, Liu J, Zeng X, Zhang Y, Hang T.

Malar J. 2014 Oct 13;13:401. doi: 10.1186/1475-2875-13-401.

16.

A new validated liquid chromatographic method for the determination of loratadine and its impurities.

Ramulu G, Ravindra Kumar Y, Vyas K, Suryanarayana MV, Mukkanti K.

Sci Pharm. 2011 Apr-Jun;79(2):277-91. doi: 10.3797/scipharm.1012-13. Epub 2011 Feb 12.

17.

Separation and estimation of process-related impurities of gefitinib by reverse-phase high-performance liquid chromatography.

Chandrashekara KA, Udupi A, Reddy CG.

J Chromatogr Sci. 2014 Sep;52(8):799-805. doi: 10.1093/chromsci/bmt116. Epub 2013 Jul 29.

PMID:
23897663
18.

Stability Indicating RP-HPLC Method for Estimation of Potential Impurities in Ledipasvir and Characterization of a New Degradation Impurity.

Siva Kumar R, Sravan Kumar KV, Kondareddy L, Yogeshwara KR, Manish G, Jeenet J, Nitesh K.

J Chromatogr Sci. 2018 Feb 21. doi: 10.1093/chromsci/bmx084. [Epub ahead of print]

PMID:
29474520
19.

Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS.

Rao RN, Raju AN, Narsimha R, Babu GR.

J Sep Sci. 2008 Jan;31(1):107-18.

PMID:
18080239
20.

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.

Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.

Clin Ther. 2009 Sep;31(9):1908-21. doi: 10.1016/j.clinthera.2009.09.001.

PMID:
19843481

Supplemental Content

Support Center